Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.99)
# 542
Out of 5,067 analysts
232
Total ratings
50.7%
Success rate
10.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $185 → $205 | $180.90 | +13.32% | 12 | Nov 17, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $7.41 | +156.41% | 5 | Nov 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $178 → $173 | $141.25 | +22.48% | 31 | Nov 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $122 → $129 | $106.58 | +21.04% | 14 | Oct 16, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $65 → $77 | $43.84 | +75.64% | 3 | Sep 29, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $43.56 | +81.36% | 5 | Sep 17, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $76 → $71 | $79.83 | -11.06% | 13 | Aug 20, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Overweight | $35 → $28 | $12.93 | +116.55% | 7 | Aug 18, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $20 → $21 | $10.36 | +102.70% | 4 | Aug 18, 2025 | |
| ERAS Erasca | Downgrades: Equal-Weight | $4 → $2 | $2.89 | -30.80% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $6.74 | +92.88% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $9.89 | +992.01% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $32.78 | +67.79% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $23.90 | +0.42% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $94.11 | -9.68% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $29.37 | -8.07% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $9.14 | -45.30% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $67.21 | -0.31% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.27 | +277.56% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.40 | +185.71% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $2.40 | +66.67% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $7.49 | +86.92% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $4.37 | +14.42% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $3.17 | -5.36% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $2.12 | +560.38% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.93 | +418.13% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $42.25 | -47.93% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.68 | +1,434.09% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.17 | +5,028.21% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.10 | +46.34% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $14.11 | +4,492.49% | 6 | May 8, 2020 |
Jazz Pharmaceuticals
Nov 17, 2025
Maintains: Overweight
Price Target: $185 → $205
Current: $180.90
Upside: +13.32%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $7.41
Upside: +156.41%
Neurocrine Biosciences
Nov 11, 2025
Maintains: Overweight
Price Target: $178 → $173
Current: $141.25
Upside: +22.48%
Rhythm Pharmaceuticals
Oct 16, 2025
Maintains: Overweight
Price Target: $122 → $129
Current: $106.58
Upside: +21.04%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Overweight
Price Target: $65 → $77
Current: $43.84
Upside: +75.64%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $43.56
Upside: +81.36%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $76 → $71
Current: $79.83
Upside: -11.06%
Cullinan Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $12.93
Upside: +116.55%
Contineum Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $20 → $21
Current: $10.36
Upside: +102.70%
Erasca
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $2.89
Upside: -30.80%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $6.74
Upside: +92.88%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $9.89
Upside: +992.01%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $32.78
Upside: +67.79%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $23.90
Upside: +0.42%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $94.11
Upside: -9.68%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $29.37
Upside: -8.07%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $9.14
Upside: -45.30%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $67.21
Upside: -0.31%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $9.27
Upside: +277.56%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.40
Upside: +185.71%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $2.40
Upside: +66.67%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $7.49
Upside: +86.92%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $4.37
Upside: +14.42%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $3.17
Upside: -5.36%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $2.12
Upside: +560.38%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.93
Upside: +418.13%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $42.25
Upside: -47.93%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.68
Upside: +1,434.09%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.17
Upside: +5,028.21%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.10
Upside: +46.34%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $14.11
Upside: +4,492.49%